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Abstract
Introduction:  Nasopharyngeal  carcinoma  is  the  most  common  cancer  originating  from  the  naso-
pharynx.
Objective: To  study  the  mechanisms  of  nasopharyngeal  carcinoma,  we  analyzed  GSE12452
microarray  data.
Methods:  GSE12452  was  downloaded  from  the  Gene  Expression  Omnibus  database  and  included
31 nasopharyngeal  carcinoma  samples  and  10  normal  nasopharyngeal  tissue  samples.  The  differ-
entially expressed  genes  were  screened  by  ANOVA  in  the  PGS  package.  Using  the  BiNGO  plugin  in
Cytoscape and  pathway  enrichment  analysis  in  the  PGS  package,  functional  and  pathway  enrich-
ment analyses  were  performed  separately  to  predict  potential  functions  of  the  differentially
expressed  genes.  Furthermore,  Transcription  factor-differentially  expressed  gene  pairs  were
searched, and  then  the  transcription  factor-differentially  expressed  gene  regulatory  network
was visualized  using  Cytoscape  software.
Results:  A  total  of  487  genes  were  screened  as  differentially  expressed  genes  between  the
nasopharyngeal  carcinoma  samples  and  the  normal  nasopharyngeal  tissue  samples.  Enrich-
ment analysis  indicated  that  PTGS2  was  involved  in  the  regulation  of  biological  process  and
small cell  lung  cancer.  ZIC2  and  OVOL1  may  function  in  nasopharyngeal  carcinoma  through
targeting signiﬁcantly  up-regulated  genes  (such  as  PTGS2,  FN1,  CXCL9  and  CXCL10)  in  the
Transcription  factor-differentially  expressed  gene  regulatory  network  (e.g.,  ZIC2→PTGS2  and
OVOL1→CXCL10).
Conclusion:  PTGS2,  FN1,  CXCL9,  CXCL10,  ZIC2  and  OVOL1  might  play  roles  in  nasopharyngeal
carcinoma.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published
by Elsevier  Editora  Ltda.  This  is  an  open  access  article  under  the  CC  BY  license  (http://
creativecommons.org/licenses/by/4.0/). Please cite this article as: Jiang X, Feng L, Dai B, Li L, Lu W. Identiﬁcation of key genes involved in nasopharyngeal carcinoma. Braz J
Otorhinolaryngol. 2016. http://dx.doi.org/10.1016/j.bjorl.2016.09.003
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Identiﬁcac¸ão  dos  principais  genes  envolvidos  no  carcinoma  nasofaríngeo
Resumo
Introduc¸ão:  O  Carcinoma  Nasofaríngeo  (CNF)  é  o  câncer  mais  comum  originário  da  nasofaringe.
Objetivo:  Estudar  os  mecanismos  de  CNF;  dados  do  microarray  GSE12452  foram  analisados.
Método: GSE12452  foi  obtido  da  base  de  dados  Gene  Expression  Omnibus  e  inclui  31  amostras
de CNF  e  10  amostras  de  tecido  nasofaríngeo  normal.  Os  Genes  Diferencialmente  Expressos
(GDE) foram  analisados  por  ANOVA  no  kit  PGS.  Usando  o  plugin  BiNGO  no  Cytoscape  e  análise
de enriquecimento  da  via  no  kit  PGS,  análises  de  enriquecimento  funcional  e  da  via  foram
realizadas separadamente  para  prever  as  potenciais  func¸ões  dos  GDE.  Além  disso,  os  pares
Fator de  Transcric¸ão  (TF)-GDE  foram  pesquisados  e  em  seguida  a  rede  reguladora  de  TF-GDE  foi
visualizada  usando  o  programa  Cytoscape.
Resultados:  Um  total  de  487  genes  foram  analisados  como  GDE  entre  as  amostras  de  CNF  e
amostras  de  tecido  nasofaríngeo  normal.  A  análise  de  enriquecimento  indicou  que  PTGS2  estava
envolvido  na  regulac¸ão  do  processo  biológico  e  câncer  pulmonar  de  pequenas  células.  ZIC2  e
OVOL1 podem  funcionar  no  CNF  almejando-se  de  maneira  signiﬁcativa  os  genes  suprarregulados
(como o  PTGS2,  FN1,  CXCL9  e  CXCL10)  na  rede  reguladora  de  TF-GDE  (p.ex.,  ZIC2→PTGS2  e
OVOL1→CXCL10).
Conclusão:  PTGS2,  FN1,  CXCL9,  CXCL10,  ZIC2  e  OVOL1  podem  desempenhar  alguns  papéis  no
CNF.
© 2016  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado
por Elsevier  Editora  Ltda.  Este e´  um  artigo  Open  Access  sob  uma  licenc¸a  CC  BY  (http://
creativecommons.org/licenses/by/4.0/).
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Antroduction
s  the  most  common  cancer  originating  from  the  naso-
harynx,  nasopharyngeal  carcinoma  (NPC)  caused  approx-
mately  86,700  new  cases  and  50,800  deaths  globally  in
012.1 NPC  is  extremely  common  in  Southeast  Asia  and
outhern  China,  with  more  than  50,000  new  cases  each
ear.2,3 NPC  can  be  induced  by  multiple  factors  including
eredity,  viral  factors  and  environmental  inﬂuences.4 Most
ases  of  NPC  are  correlated  with  Epstein--Barr  Virus  (EBV)
nfection,  which  is  a  B-lymphotropic  herpesvirus  possessing
rowth-transforming  properties.5 Therefore,  it  is  of  great
mportance  to  study  the  mechanisms  of  NPC.
Many  studies  investigating  the  mechanisms  of  NPC  have
een  published.  There  are  several  genes  (such  as  C-myc,
KT1,  p53,  MDM2,  LMP1  and  PTEN)  implicated  in  the  patho-
enesis  of  NPC  because  they  are  often  ampliﬁed  or  altered  in
atients  with  this  disease.6--8 Disabled  2  (DAB2)  is  frequently
own-regulated  by  promoter  hypermethylation  and  may  be
 potential  tumor  suppressor  in  NPC.9 Previous  studies  show
hat  the  potential  tumor  suppressor  gene  A  disintegrin-
ike  and  metalloprotease  domain  with  thrombospondin  type
 motifs  9  (ADAMTS9)  is  closely  related  to  lymph  node
etastases,  and  it  can  inhibit  tumor  growth  by  suppress-
ng  angiogenesis  in  NPC.10,11 The  transcription  factor  (TF)
daptor-related  protein  complex  1  (AP-1)  activated  by  the
BV-encoded  Nuclear  Antigen  1  (EBNA1)  can  target  hypoxia-
nducible  factor-1,  interleukin  8  and  Vascular  Endothelial
rowth  Factor  (VEGF),  which  promotes  microtubule  forma-
ion  in  NPC  cells.12 The  TF  Forkhead  Box  M1  (FOXM1)  is
nvolved  in  tumor  development,  and  the  adenovirus  vector
dFOXM1shRNA,  which  expresses  FOXM1-speciﬁc  short  hair-
in  RNA,  may  be  used  as  a  therapeutic  intervention  for  the
s
r
w
freatment  of  patients  with  NPC.13 By  down-regulating  the
xpression  of  Secreted  Protein,  Acidic  and  Rich  in  Cysteine
SPARC),  TF  sex  determining  region  Y-box  5  (SOX-5)  functions
n  the  progression  of  NPC  and  may  be  used  as  a  predictor  for
oor  NPC  prognosis.14,15 Although  these  studies  have  been
erformed  to  investigate  NPC,  the  mechanisms  of  NPC  still
emain  unclear.
In 2006,  Sengupta  et  al.  analyzed  the  expression  of
ll  latent  EBV  genes  between  NPC  samples  and  normal
asopharyngeal  epithelium  samples,  and  obtained  a  panel
f  differentially  expressed  genes  (DEGs).3 Using  the  same
ata  that  was  used  by  Sengupta  et  al.,3 we  not  only  screened
he  DEGs  but  also  performed  a  comprehensive  bioinformatic
nalysis  to  identify  key  genes  associated  with  NPC.  The
otential  functions  of  the  DEGs  were  predicted  by  functional
nd  pathway  enrichment  analyses.  In  addition,  a  TF-DEG
egulatory  network  was  constructed  to  investigate  the  reg-
latory  relationships  between  TFs  and  DEGs.
ethods
icroarray  data
he  GSE12452  expression  proﬁle  data  deposited  by  Sengupta
t  al.3 was  downloaded  from  the  Gene  Expression  Omnibus
GEO,  http://www.ncbi.nlm.nih.gov/geo/)  database,  which
as  based  on  the  platform  of  the  GPL570  [HG-U133  Plus  2]
ffymetrix  Human  Genome  U133  Plus  2.0  Array.  The
pecimens  included  31  NPC  samples  and  10  normal  nasopha-
yngeal  tissue  samples  collected  from  patients  from  Taiwan
ith  informed  consent.  The  samples  were  resected,  fast
rozen  and  then  stored  in  liquid  nitrogen.
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Figure  1  The  volcano  plot  for  differentially  expressed  genes
(DEGs) (FC  >  2  and  adjusted  p-value  <  0.05).  The  horizontal  axis
represents  the  fold  change,  and  the  vertical  axis  represents
the adjusted  p-value.  The  red  and  blue  circles  indicate  up-  and
down-regulated  genes,  respectively.
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Mechanisms  of  NPC  
Screening  for  DEGs
For  the  GSE12452  dataset,  the  Robust  MultiArray  Aver-
aging  (RMA)  method  in  the  Partek® Genomics  SuiteTM
(PGS)  (http://www.partek.com/)  package16 was  used  for
preprocessing,  including  background  adjustment,  quantile
normalization  and  log  2  transformation.  After  batch  correc-
tion,  the  processed  expression  matrix  was  obtained.  The
ANOVA  (analysis  of  variance)  method  in  the  PGS  package16
was  used  to  compare  the  DEGs  between  the  NPC  samples
and  the  normal  nasopharyngeal  tissue  samples.  The  p-values
obtained  were  adjusted  for  multiple  testing  using  the  Ben-
jamini  and  Hochberg  method.17 Genes  with  fold-change  (FC)
>2  and  adjusted  p-value  <  0.05  were  selected  as  DEGs.
Functional  and  pathway  enrichment  analysis
Gene  Ontology  (GO)  terms  can  be  used  to  describe  three
types  of  gene  products  including  biological  process  in
which  they  implicated,  their  molecular  function  and  sub-
cellular  location.18 The  Kyoto  Encyclopedia  of  Genes  and
Genomes  (KEGG)  is  a  database  composed  of  genes  and
their  functional  information.19 Using  the  BiNGO  plugin20
in  Cytoscape  (http://www.cytoscape.org/)  and  pathway
enrichment  analysis  in  the  PGS  package,16 GO  and  KEGG
pathway  enrichment  analyses  were  performed  separately
for  DEGs  between  the  NPC  samples  and  the  normal  nasopha-
ryngeal  tissue  samples.  The  adjusted  p-value  <  0.05  was  used
as  the  cut-off  criterion.
TF-DEG  regulatory  network  construction
The  Genomatix  Software  Suite  (https://www.genomatix.
de/)  package21 was  used  to  predict  Transcription  Factors
(TFs).  In  brief,  the  Gene2Promoter  (http://www.genomatix.
de)  tool22 was  used  to  extract  promoter  sequences  of  cor-
responding  DEGs  from  the  Genomatix  database.  Then,  the
TFs  were  analyzed  using  the  MatInspector  tool.21 TFs  with  a
p-value  of  <0.05  and  FC  >  2  were  selected  as  differentially
expressed  TFs,  and  then  their  corresponding  TF-DEG  pairs
were  screened.  Finally,  the  TF-DEG  regulatory  network  was
visualized  using  Cytoscape  software.23
Results
Analysis  of  DEGs
After  GSE12452  was  downloaded,  the  expression  proﬁle
data  were  preprocessed  and  then  the  DEGs  were  identi-
ﬁed  by  ANOVA  using  the  PGS  package.  The  volcano  plot  for
DEGs  separately  is  shown  in  Fig.  1.  A  total  of  487  genes
were  selected  as  DEGs  between  the  NPC  samples  and  the
normal  nasopharyngeal  tissue  samples,  including  122  up-
regulated  and  365  down-regulated  genes.  The  number  of
down-regulated  genes  was  greater  than  the  number  of  up-
regulated  genes.  In  the  heat  map  of  the  hierarchical  cluster
analysis  for  the  DEGs,  the  NPC  samples  and  normal  nasopha-
ryngeal  tissue  samples  were  clearly  divided  into  two  groups
(Fig.  2).
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cigure  2  The  heat  map  of  the  hierarchical  cluster  analysis  for
ifferentially  expressed  genes  (DEGs).
unctional  and  pathway  enrichment  analysis
he  top  10  GO  functions  for  the  up-regulated  genes  included
ollagen  ﬁbril  organization  (p  =  1.44E−06),  extracellular
atrix  organization  (p  =  6.73E−08)  and  regulation  of  bio-
ogical  process  (p  =  3.35E−06,  which  involved  prostaglandin-
ndoperoxide  synthase  2,  PTGS2)  (Table  1A).  The  enriched
EGG  pathways  for  the  up-regulated  genes  are  listed  in
able  1C,  and  these  included  amoebiasis  (p  =  1.25E−07),
CM-receptor  interaction  (p  =  9.01E−10)  and  small  cell  lung
ancer  (p  =  3.10E−06,  which  involved  PTGS2).
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Table  1  The  enriched  GO  functions  and  KEGG  pathways  for  the  up-regulated  and  the  down-regulated  genes.  (A)  The  top  10  GO
functions enriched  for  the  up-regulated  genes.  (B)  The  top  10  GO  functions  enriched  for  the  down-regulated  genes.  (C)  The  top
10 KEGG  pathways  enriched  for  the  up-regulated  genes.  (D)  The  top  10  KEGG  pathways  enriched  for  the  down-regulated  genes.
Term  Description  Gene  number  Gene  symbol  p-Value
A
30198  Extracellular  matrix  organization  9  COL18A1,  COL4A2. .  .. .  .  6.73E−08
30199 Collagen  ﬁbril  organization 5  COL3A1,  COL1A2. .  .. . . 1.44E−06
43062 Extracellular  structure  organization 9  COL3A1,  COL1A2. .  .. . . 2.85E−06
50789 Regulation  of  biological  process 72  PTGS2,  EZH2.  . .. .  . 3.35E−06
32964 Collagen  biosynthetic  process 3  COL1A1,  COL5A1,  COL5A1 3.91E−06
43588 Skin  development  5  COL5A2,  COL5A1. .  .. . . 4.77E−06
65007 Biological  regulation  74  SLC9A7,  PTGS2.  . .. .  .  6.95E−06
6950 Response  to  stress  30  C3AR1,  PTGS2.  .  .. .  .  8.65E−06
9611 Response  to  wounding  15  BMP2,  TNFSF4.  . .. .  .  1.03E−05
6954 Inﬂammatory  response  11  CXCL9,  PLA2G7. .  .. . .  2.15E−05
B
10880 Regulation  of  release  of  sequestered
calcium  ion  into  cytosol  by
sarcoplasmic  reticulum
4  CALM3,  FKBP1B.  .  .. .  . 2.32E−07
30855 Epithelial  cell  differentiation  13  EREG,  ELF3.  .  .. .  .  1.30E−06
60316 Positive  regulation  of
ryanodine-sensitive  calcium-release
channel  activity
3  CALM2,  CALM1,  CALM1  3.21E−06
60314 Regulation  of  ryanodine-sensitive
calcium-release  channel  activity
4  FKBP1B,  CALM2.  .  .. .  . 9.20E−06
60315 Negative  regulation  of
ryanodine-sensitive  calcium-release
channel  activity
3  CALM3,  CALM2,  CALM1 1.27E−05
7017 Microtubule-based  process  14  TPPP3,  DNAH9.  .  .. . .  1.92E−05
8544 Epidermis  development  12  CST6,  EREG.  .  .. .  . 2.15E−05
1539 Ciliary  or  ﬂagellar  motility  4  TEKT2,  DNAH2.  .  .. .  . 3.02E−05
7018 Microtubule-based  movement  9  DNAH2,  DNAH7.  .  .. .  . 3.72E−05
30216 Keratinocyte  differentiation  7  PPL,  CNFN.  .  .. .  . 3.90E−05
Description Gene  number  Gene  symbol  p-Value
C
ECM-receptor  interaction  11  COL1A1,  COL1A2. . .. .  . 9.01E−10
Protein digestion  and  absorption  10  COL1A2,  COL3A1. . .. .  . 9.05E−09
Amoebiasis 10  CD14,  COL1A2. . .. .  .  1.25E−07
Small cell  lung  cancer  8  PTGS2,  FN1. .  .. .  .  3.10E−06
Staphylococcus  aureus  infection  5  C3AR1,  FCGR2A. . .. .  . 2.66E−04
Osteoclast differentiation  6  SOCS1,  TYK2.  .  .. . .  2.23E−03
Toll-like receptor  signaling  pathway  5  CXCL9,  NFKBIA.  . .. .  . 4.54E−03
DNA replication  3  PCNA,  MCM2.  .  .. .  .  6.36E−03
Leishmaniasis  4  FCGR2A,  PTGS2.  .  .. .  .  6.94E−03
Cell cycle  5  CCNE2,  SMC1A.  . .. .  . 9.53E−03
D
Drug metabolism-cytochrome  P450  9  ADH1  C,  ADH7.  .  .. .  .  3.02E−07
Metabolism of  xenobiotics  by  cytochrome  P450  8  ADH7,  ALDH1A3.  .  .. .  .  8.48E−06
Tyrosine metabolism  5  ALDH3A1,  ALDH3B2. .  .. .  .  1.69E−04
Glycolysis/gluconeogenesis  6  ADH7,  ALDH1A3.  .  .. .  .  2.51E−04
Histidine metabolism  4  ALDH3A1,  ALDH3A2.  . .. .  .  5.74E−04
beta-Alanine  metabolism  4  ALDH3A2,  ALDH3B2. .  .. .  .  6.59E−04
Phenylalanine  metabolism  3  ALDH1A3,  ALDH3A1,  ALDH3B2  1.88E−03
Tight junction  7  CGN,  CLDN7.  . .. . . 2.40E−03
Phototransduction  3  CALM1,  CALM2,  CALM3  7.52E−03
Retinol metabolism  4  DHRS9,  SDR16C5. .  .. .  .  1.03E−02
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Figure  3  The  regulatory  network  of  Transcription  Factors  (TFs,  such  as  ZIC2,  OVOL  and  HES1)  and  their  targeted  differentially
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Similarly,  functional  and  pathway  enrichment  analyses
were  performed  for  the  down-regulated  genes.  As  shown  in
Table  1B,  the  functions  including  the  regulation  of  release
of  sequestered  calcium  ion  into  the  cytosol  by  sarcoplas-
mic  reticulum  (p  =  2.32E−07),  epithelial  cell  differentiation
(p  =  1.30E−06)  and  positive  regulation  of  ryanodine-
sensitive  calcium-release  channel  activity  (p  =  3.21E-06)
were  enriched.  The  enriched  pathways  included  drug
metabolism-cytochrome  P450  (p  =  3.02E−07),  metabolism  of
xenobiotics  by  cytochrome  P450  (p  =  8.48E−06) and  tyrosine
metabolism  (p  =  1.69E−04)  (Table  1D).
TF-DEG  regulatory  network  analysis
Using  the  Genomatix  Software  Suite  package,  TFs  were  pre-
dicted  for  the  122  up-regulated  and  365  down-regulated
genes.  There  were  up-regulated  TFs  targeting  up-regulated
or  down-regulated  genes,  as  well  as  down-regulated  TFs  tar-
geting  up-regulated  or  down-regulated  genes.  However,  only
TFs  that  targeted  both  up-regulated  and  down-regulated
genes  were  selected.  The  TF-DEG  regulatory  network  of
TFs  (Zic  family  member  2,  ZIC2;  ovo-like  1,  OVOL1;  and
hairy  and  enhancer  of  split  1,  HES1)  and  their  targeted
DEGs  are  shown  in  Fig.  3.  In  particular,  signiﬁcantly  up-
regulated  PTGS2,  ﬁbronectin  (FN1)  and  chemokine  (C-X-C
motif)  ligand  9  (CXCL9)  were  targeted  and  activated  by  ZIC2.
Nevertheless,  signiﬁcantly  up-regulated  chemokine  (C--X--C
motif)  ligand  10  (CXCL10)  was  targeted  and  suppressed  by
OVOL1.
i
T
miscussion
n  this  study,  a  total  of  487  genes  were  selected  as
EGs  between  NPC  samples  and  normal  nasopharyngeal
issue  samples,  including  122  up-regulated  and  365  down-
egulated  genes.  There  were  many  functions  enriched  for
he  DEGs,  such  as  extracellular  matrix  organization  and
xtracellular  structure  organization.  PTGS2,  FN1,  CXCL9
nd  CXCL10  were  signiﬁcantly  up-regulated  genes  involved
n  the  TF-DEG  regulatory  network,  and  they  may  func-
ion  in  NPC  through  ZIC2  or  OVOL1  (e.g.,  ZIC2→PTGS2  and
VOL1→CXCL10).
Enrichment  analysis  indicated  that  PTGS2  was  involved
n  the  regulation  of  biological  process  and  small  cell  lung
ancer.  As  a  downstream  gene  involved  in  the  NF-B  path-
ay,  PTGS2  is  also  referred  to  as  cyclooxygenase-2  (COX-2).
t  is  known  that  COX2  can  regulate  cancer  stem-like  cells  of
PC  cells  and  promote  their  characteristics.  Furthermore,
arthenolide  may  function  in  targeted  chemotherapy  via  the
F-B/COX2  pathway.24 Based  on  PCR  and  restriction  frag-
ent  length  polymorphism  analysis,  the  COX2  −765  G>C
unctional  promoter  polymorphism  may  be  related  to  risk
nd  neoplastic  progression  of  NPC.25 The  results  of  immuno-
istochemistry  and  semiquantitative  assessment  show  that
OX-2  expression  increases  as  the  nasopharyngeal  epithe-
ium  develops  from  normal  to  dysplastic  and  then  into  NPC,
ndicating  that  COX-2  promotes  the  development  of  NPC.26,27
his  suggests  that  PTGS2  might  be  associated  with  NPC.
It  is  known  that  FN1  contributes  to  tumorigenesis  by  pro-
oting  the  growth  and  migration  of  tumor  cells,  as  well  as  by
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nhancing  resistance  to  therapy.28,29 Up-regulated  FN1  cor-
elates  with  the  epithelial  to  mesenchymal  transition  (EMT)
nd  contributes  to  tumor  cell  metastasis;  therefore,  it  may
e  used  as  a  potential  diagnostic  marker  and  therapeutic  tar-
et  of  NPC.30 Based  on  a  multiplex  suspension  array  system,
 previous  study  found  that  CXCL9  expression  is  signiﬁcantly
p-regulated  in  patients  with  NPC  and  oral  cavity  squa-
ous  cell  carcinoma.31,32 Quantitative  real-time  PCR  and
mmunohistochemistry  suggested  that  up-regulated  CXCL9
s  related  to  the  aggressiveness  of  NPC,  and  an  enzyme-
inked  immunosorbent  assay  indicated  that  its  serum  level
ay  be  a  valuable  prognostic  indicator.33 The  ZIC  genes,
hich  consist  of  ﬁve  Cys2His2  zinc-ﬁnger  domains,  encode
inc-ﬁnger  Transcription  Factors.34 Among  the  family  mem-
ers,  ZIC2  mediates  the  tissue-speciﬁc  expression  of  the
-protein  coupled  receptor  dopamine  receptor  D1.35 ZIC2
xpression  is  up-regulated  in  several  malignant  tumors,
ncluding  synovial  sarcoma,  pediatric  medulloblastoma  and
ndometrial  cancers.36--38 Therefore,  the  expression  levels
f  FN1,  CXCL9  and  ZIC2  might  be  correlated  with  NPC.  In
he  TF-DEG  regulatory  network,  we  found  that  ZIC2  targeted
nd  activated  FN1,  CXCL9  and  PTGS2,  indicating  that  ZIC2
ight  also  function  in  NPC  by  regulating  FN1,  CXCL9  and
TGS2.
It  is  reported  that  the  TFs  OVOL1  and  OVOL2  play  crit-
cal  roles  in  inducing  the  transition  from  mesenchymal  to
pithelial  (MET)  in  several  types  of  human  cancers.39 As
 member  of  the  CXC  chemokine  family,  CXCL10  binds  to
ts  receptor  CXCR3  to  exert  biological  functions  in  infec-
ious  diseases,  immune  dysfunction,  chronic  inﬂammation,
umor  development  and  metastasis.40 The  ELR-negative
XC  chemokine  CXCL10  can  attenuate  angiogenesis  and
uppress  tumors.41 Overexpression  of  CXCL10  and  CXCR3
lay  essential  roles  in  advanced  cancers,  such  as  basal
ell  carcinoma,42 B-cell  lymphoma,43 multiple  myeloma44
nd  ovarian  carcinoma.45 Inﬂammatory  cytokines  including
XCL10,  Macrophage-Inhibitory-Protein  1  (MIP1)  and  inter-
eukin  1  alpha  are  overexpressed  in  malignant  NPC  cells,
hich  may  promote  the  leukocyte  inﬁltrate.46 These  results
uggest  that  OVOL1  and  CXCL10  might  be  correlated  with
PC.  In  the  TF-DEG  regulatory  network,  we  also  found
hat  OVOL1  targeted  and  repressed  CXCL10,  suggesting
hat  OVOL1  might  also  play  a  role  in  NPC  by  mediating
XCL10.
onclusion
n  summary,  we  used  GSE12452  expression  proﬁle  data  down-
oaded  from  GEO  to  study  the  mechanisms  of  NPC.  A  total
f  487  genes  were  selected  as  DEGs  between  the  NPC  sam-
les  and  the  normal  nasopharyngeal  tissue  samples.  Several
enes  (PTGS2,  FN1,  CXCL9,  CXCL10,  ZIC2  and  OVOL1)  might
lay  roles  in  NPC  and  might  also  be  used  for  targeted  therapy
f  NPC  in  clinical  practice.  However,  further  experimental
alidation  is  still  required  to  unravel  their  mechanisms  of
ction  in  NPC.onﬂicts of interest
he  authors  declare  no  conﬂicts  of  interest.
1 PRESS
Jiang  X  et  al.
eferences
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal
A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:
87--108.
2. Chang ET, Adami H-O. The enigmatic epidemiology of nasopha-
ryngeal carcinoma. Cancer Epidemiol Biomark Prev. 2006;15:
1765--77.
3. Sengupta S, Den Boon JA, Chen I-H, Newton MA, Dahl DB,
Chen M, et al. Genome-wide expression proﬁling reveals
EBV-associated inhibition of MHC class I expression in nasopha-
ryngeal carcinoma. Cancer Res. 2006;66:7999--8006.
4. Tsao SW,  Yip YL, Tsang CM, Pang PS, Lau VMY, Zhang G, et al.
Etiological factors of nasopharyngeal carcinoma. Oral Oncol.
2014;50:330--8.
5. Tay JK, Chan SH, Lim CM, Siow CH, Goh HL, Loh KS. The role of
Epstein--Barr virus DNA load and serology as screening tools for
nasopharyngeal carcinoma. Otolaryngol Head Neck Surg. 2016,
http://dx.doi.org/10.1177/0194599816641038.
6. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded
latent membrane proteins LMP1 and LMP2 in the pathogene-
sis of nasopharyngeal carcinoma (NPC). In: Seminars in cancer
biology. Elsevier; 2012.
7. Jiang Q, Zhang Y, Zhao M, Li Q, Chen R, Long X, et al. miR-16
induction after CDK4 knockdown is mediated by c-Myc suppres-
sion and inhibits cell growth as well as sensitizes nasopharyngeal
carcinoma cells to chemotherapy. Tumor Biol. 2016;37:
2425--33.
8. Zhang X, Chen X, Zhai Y, Cui Y, Cao P, Zhang H, et al. Com-
bined effects of genetic variants of the PTEN, AKT1, MDM 2 and
p53 genes on the risk of nasopharyngeal carcinoma. PLoS ONE.
2014;9:e92135.
9. Tong JH, Ng DC, Chau SL, So KK, Leung PP, Lee TL, et al. Putative
tumour-suppressor gene DAB2 is frequently down regulated by
promoter hypermethylation in nasopharyngeal carcinoma. BMC
Cancer. 2010;10:253.
0. Lung HL, Lo PHY, Xie D, Apte SS, Cheung AKL, Cheng Y, et al.
Characterization of a novel epigenetically-silenced, growth-
suppressive gene, ADAMTS9, and its association with lymph
node metastases in nasopharyngeal carcinoma. Int J Cancer.
2008;123:401--8.
1. Lo PHY, Lung HL, Cheung AKL, Apte SS, Chan KW, Kwong FM,
et al. Extracellular protease ADAMTS9 suppresses esophageal
and nasopharyngeal carcinoma tumor formation by inhibiting
angiogenesis. Cancer Res. 2010;70:5567--76.
2. O’Neil JD, Owen TJ, Wood VH, Date KL, Valentine R, Chuk-
wuma MB, et al. Epstein--Barr virus-encoded EBNA1 modulates
the AP-1 transcription factor pathway in nasopharyngeal car-
cinoma cells and enhances angiogenesis in vitro. J Gen Virol.
2008;89:2833--42.
3. Chen H, Yang C, Yu L, Xie L, Hu J, Zeng L, et al.
Adenovirus-mediated RNA interference targeting FOXM1 tran-
scription factor suppresses cell proliferation and tumor
growth of nasopharyngeal carcinoma. J Gene Med. 2012;14:
231--40.
4. Huang DY, Lin YT, Jan PS, Hwang YC, Liang ST, Peng Y,
et al. Transcription factor SOX-5 enhances nasopharyngeal car-
cinoma progression by down-regulating SPARC gene expression.
J Pathol. 2008;214:445--55.
5. Wang HY, Li YY, Shao Q, Hou JH, Wang F, Cai MB, et al. Secreted
protein acidic and rich in cysteine (SPARC) is associated with
nasopharyngeal carcinoma metastasis and poor prognosis. J
Transl Med. 2012;10:10--7.
6. Maiti S. Comprehensive assessment of CNV calling algorithms: a
family based study involving monozygotic twins discordant for
schizophrenia; 2012.
7. Haynes W.  Benjamini--Hochberg method. In: Encyclopedia of
systems biology. Springer; 2013. p. 78.
 IN+Model
3
3
3
3
3
3
3
4
4
4
4
4
4ARTICLE
Mechanisms  of  NPC  
18. Consortium GO. Gene ontology consortium: going forward.
Nucleic Acids Res. 2015;43:D1049--56.
19. Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M.
KEGG as a reference resource for gene and protein annotation.
Nucleic Acids Res. 2015, gkv1070.
20. Maere S, Heymans K, Kuiper M. BiNGO: a Cytoscape plugin to
assess overrepresentation of gene ontology categories in bio-
logical networks. Bioinformatics. 2005;21:3448--9.
21. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klin-
genhoff A, et al. MatInspector and beyond: promoter analysis
based on transcription factor binding sites. Bioinformatics.
2005;21:2933--42.
22. Scherf M, Klingenhoff A, Werner T. Highly speciﬁc localization
of promoter regions in large genomic sequences by Promo-
terInspector: a novel context analysis approach. J Mol Biol.
2000;297:599--606.
23. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape
2.8: new features for data integration and network visualiza-
tion. Bioinformatics. 2011;27:431--2.
24. Liao K, Xia B, Zhuang Q-Y, Hou M-J, Zhang Y-J, Luo B,
et al. Parthenolide inhibits cancer stem-like side population
of nasopharyngeal carcinoma cells via suppression of the NF-
B/COX-2 pathway. Theranostics. 2015;5:302.
25. Ben Nasr H, Chahed K, Bouaouina N, Chouchane L. PTGS2
(COX-2)− 765 G>C functional promoter polymorphism and its
association with risk and lymph node metastasis in nasopharyn-
geal carcinoma. Mol Biol Rep. 2009;36:193--200.
26. Tan KB, Putti TC. Cyclooxygenase 2 expression in nasopharyn-
geal carcinoma: immunohistochemical ﬁndings and potential
implications. J Clin Pathol. 2005;58:535--8.
27. Shi D, Xiao X, Tian Y, Qin L, Xie F, Sun R, et al. Acti-
vating enhancer-binding protein-2 induces cyclooxygenase-2
expression and promotes nasopharyngeal carcinoma growth.
Oncotarget. 2015;6:5005.
28. Jia D, Entersz I, Butler C, Foty RA. Fibronectin matrix-mediated
cohesion suppresses invasion of prostate cancer cells. BMC Can-
cer. 2012;12:1.
29. Bae YK, Kim A, Kim MK, Choi JE, Kang SH, Lee SJ. Fibronectin
expression in carcinoma cells correlates with tumor aggressive-
ness and poor clinical outcome in patients with invasive breast
cancer. Hum Pathol. 2013;44:2028--37.
30. Ma LJ, Lee SW, Lin LC, Chen TJ, Chang IW, Hsu HP, et al.
Fibronectin overexpression is associated with latent membrane
protein 1 expression and has independent prognostic value for
nasopharyngeal carcinoma. Tumor Biol. 2014;35:1703--12.
31. Chang KP, Chang YT, Liao CT, Yen TC, Chen IH, Chang YL,
et al. Prognostic cytokine markers in peripheral blood for
oral cavity squamous cell carcinoma identiﬁed by multi-
plexed immunobead-based proﬁling. Clin Chim Acta. 2011;412:
980--7.
32. Chang KP, Wu  CC, Chen HC, Chen SJ, Peng PH, Tsang NM, et al.
Identiﬁcation of candidate nasopharyngeal carcinoma serum
4 PRESS
7
biomarkers by cancer cell secretome and tissue transcriptome
analysis: potential usage of cystatin A for predicting nodal stage
and poor prognosis. Proteomics. 2010;10:2644--60.
3. Hsin LJ, Kao HK, Chen IH, Tsang NM, Hsu CL, Liu SC, et al. Serum
CXCL9 levels are associated with tumor progression and treat-
ment outcome in patients with nasopharyngeal carcinoma. PLoS
ONE. 2013;8:e80052.
4. Grinberg I, Millen K. The ZIC gene family in development and
disease. Clin Genet. 2005;67:290--6.
5. Yang Y, Hwang CK, Junn E, Lee G, Mouradian MM. ZIC2 and
Sp3 repress Sp1-induced activation of the human D1A dopamine
receptor gene. J Biol Chem. 2000;275:38863--9.
6. Bidus MA, Risinger JI, Chandramouli GV, Dainty LA, Litzi TJ,
Berchuck A, et al. Prediction of lymph node metastasis in
patients with endometrioid endometrial cancer using expres-
sion microarray. Clin Cancer Res. 2006;12:83--8.
7. Pﬁster S, Schlaeger C, Mendrzyk F, Wittmann A, Benner A,
Kulozik A, et al. Array-based proﬁling of reference-independent
methylation status (aPRIMES) identiﬁes frequent promoter
methylation and consecutive downregulation of ZIC2 in pedi-
atric medulloblastoma. Nucleic Acids Res. 2007;35:e51.
8. Fernebro J, Francis P, Edén P, Borg Å, Panagopoulos I, Mertens
F, et al. Gene expression proﬁles relate to SS18/SSX fusion type
in synovial sarcoma. Int J Cancer. 2006;118:1165--72.
9. Roca H, Hernandez J, Weidner S, McEachin RC, Fuller D, Sud S,
et al. Transcription factors OVOL1 and OVOL2 induce the mes-
enchymal to epithelial transition in human cancer. PLoS ONE.
2013;8:e76773.
0. Liu M, Guo S, Stiles JK. The emerging role of CXCL10 in cancer.
Oncol Lett. 2011;2:583--9 [review].
1. Persano L, Crescenzi M, Indraccolo S. Anti-angiogenic gene ther-
apy of cancer: current status and future prospects. Mol Aspects
Med. 2007;28:87--114.
2. Lo BKK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ.
CXCR3/ligands are signiﬁcantly involved in the tumorigenesis
of basal cell carcinomas. Am J Pathol. 2010;176:2435--46.
3. Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann
TM, Link BK, et al. Elevated pretreatment serum levels
of interferon-inducible protein-10 (CXCL10) predict disease
relapse and prognosis in diffuse large B-cell lymphoma patients.
Am J Hematol. 2012;87:865--9.
4. Pellegrino A, Antonaci F, Russo F, Merchionne F, Ribatti D, Vacca
A, et al. CXCR3-binding chemokines in multiple myeloma. Can-
cer Lett. 2004;207:221--7.
5. Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka
N, et al. Up-regulation of CXC chemokines and their receptors:
implications for proinﬂammatory microenvironments of ovarian
carcinomas and endometriosis. Hum Pathol. 2007;38:1676--87.6. Teichmann M, Meyer B, Beck A, Niedobitek G. Expression of the
interferon-inducible chemokine IP-10 (CXCL10), a chemokine
with proposed anti-neoplastic functions, in Hodgkin lymphoma
and nasopharyngeal carcinoma. J Pathol. 2005;206:68--75.
